Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma.

Kim KT, Milgrom H, Yoon YK, Levy AL, Matz P, Welch MJ, Cahn A, Collins DA, Kathman S, Mehta R, Su SF, Kunka RL.

J Clin Pharmacol. 2008 Jan;48(1):108-16.

PMID:
18094223
2.

Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.

Lumry WR, Conway MM, LaForce CF, Pearlman DS, Scott CA, Herje NE, Wu WW, Crim C.

Ann Allergy Asthma Immunol. 2006 Jan;96(1):51-9.

PMID:
16440533
3.

From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.

Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, Daley-Yates PT.

Respir Med. 2000 Jun;94 Suppl B:S10-6.

PMID:
10919680
4.

Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.

Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT.

Clin Pharmacokinet. 2000;39 Suppl 1:17-22.

PMID:
11140429
5.

Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.

Wasserman RL, Baker JW, Kim KT, Blake KV, Scott CA, Wu W, Faris MA, Crim C.

Ann Allergy Asthma Immunol. 2006 Jun;96(6):808-18.

PMID:
16802768
6.

Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.

Qaqundah PY, Sugerman RW, Ceruti E, Maspero JF, Kleha JF, Scott CA, Wu W, Mehta R, Crim C.

J Pediatr. 2006 Nov;149(5):663-670. Erratum in: J Pediatr. 2007 May;150(5):565.

PMID:
17095339
7.

Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.

Edin HM, Andersen LB, Schoaf L, Scott-Wilson CA, Ho SY, Ortega HG.

Ann Allergy Asthma Immunol. 2009 Apr;102(4):323-7. doi: 10.1016/S1081-1206(10)60338-9.

PMID:
19441604
9.
11.

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients.

Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB.

Ann Allergy Asthma Immunol. 2001 Nov;87(5):379-85.

PMID:
11730179
12.

Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function.

Lee DK, Bates CE, Currie GP, Cowan LM, McFarlane LC, Lipworth BJ.

Ann Allergy Asthma Immunol. 2004 Sep;93(3):253-8.

PMID:
15478385
15.

Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide.

Clearie KL, Williamson PA, Meldrum K, Gillen M, Carlsson LG, Carlholm M, Ekelund J, Lipworth BJ.

Br J Clin Pharmacol. 2011 Apr;71(4):504-13. doi: 10.1111/j.1365-2125.2010.03857.x.

19.

Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients.

Derom E, Van De Velde V, Marissens S, Engelst├Ątter R, Vincken W, Pauwels R.

Pulm Pharmacol Ther. 2005;18(5):328-36.

PMID:
15939311
20.

Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.

Currie GP, Fowler SJ, Wilson AM, Sims EJ, Orr LC, Lipworth BJ.

Thorax. 2002 Oct;57(10):865-8.

Supplemental Content

Support Center